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Summary Between 1975 and 1984, 125 cases of histologically confirmed soft tissue sarcomata (STS) were
registered in the Department of Clinical Oncology in Edinburgh. Of these, 100 were eligible for analysis of
prognostic factors. The overall 5-year survival rate was 21.5%. Univariate analysis demonstrated that extent of
surgery, radical versus palliative or no radiotherapy, mass as a presenting symptom, metastases at presenta-
tion, site, histological type, mitotic activity, grade and UICC stage all had a statistically significant effect on
survival. Analysis using the proportional hazard regression model was performed on the 87 patients for whom
all variables were recorded. When all histological and clinical features and treatment modalities were included
in the model then radiotherapy, surgery, necrosis, sex and mitoses were identified as independent prognostic
variables. When symptoms and treatment were excluded then the multivariate analysis identified sex and
mitotic activity as independent parameters. For the 33 superficial STS with tumour size recorded multivariate
analysis revealed size, necrosis and cellularity as independent prognostic variables. For the 31 deep STS
histological type, sex, surgery and radiotherapy were identified as independent prognostic parameters.
Various treatment modalities have been suggested for the
management of patients with soft tissue sarcomata (STS) but
their efficacy remains difficult to assess. This is made even
more difficult by the rarity and the varying histogenesis and
sites of origin of STS. Consequently relatively few prognostic
studies are available in the literature. Most of these have
used univariate analysis of survival which does not take into
account inter factor effects, though reports using multivariate
analysis have increased in the last 3 years.
In this study the data were collated from the Department
of Clinical Oncology, Edinburgh. All the histological sections
were reviewed. The aims of this paper are to describe the
clinical features at presentation, treatment modalities and the
prognostic factors for survival.
Patients and methods
Data were extracted for 142 patients referred to the Depart-
ment of Clinical Oncology with a definite or probable
diagnosis of soft tissue sarcoma (STS). Since the original
diagnoses there have been considerable changes in classific-
ation, diagnostic criteria and terminology of STS, recognition
or delineation of new categories and better understanding of
established entities. The entire group was, therefore, sub-
jected to histological review using current concepts of STS
classification.
Based on light microscopic review combined, where need-
ed, with immunoperoxidase studies and electron microscopic
examination 125 cases were confirmed as STS and 17 cases
were changed to benign soft tissue lesions (9) and non-
sarcomatous malignancies (8); these 17 cases were excluded
from the survival analysis. The other major diagnostic altera-
tions in the overall group (142 cases) were an increase in
leiomyosarcoma (25-37), malignant fibrous histiocytoma-MFH
(18-35), synovial sarcoma (5-14) and neurogenic sarcoma
(3-6) and a reduction in fibrosarcoma (22-2), liposarcoma
(25-13), rhabdomyosarcoma (7-3) and sarcoma not other-
wise specified (26-3).
Twenty-five of the 125 confirmed STS patients had been
referred following local recurrence, the development of
metastases or both. They were excluded from this study
leaving a total of 100 STS for analysis. Minimum follow-up
was 5 years except for one patient lost to follow-up at 27
months.
The tumours were staged retrospectively using the UICC
TNM (1987) staging system recommended by the American
Joint Committee (AJC) (Russell et al., 1977).
Pathology
The original histological material from the 142 patients was
reviewed by two of us (J.N.J. and K.M.McL.) without know-
ledge of either previous pathological assessment or clinical
outcome. The histological criteria used in making the diag-
nosis were those of Enzinger and Weiss (1988). The patho-
logical size was extracted from the histological reports. The
microscopic features studied for each histological type were
mitotic activity, pleomorphism, cellularity, necrosis and
grade. The mitotic figures were counted in multiples (the
number depended on the case) of 10 x 400 fields and a mean
was calculated; the high power field (hpf) area was 0.1591
mm2. We assessed necrosis macro- and microscopically and
in conclusion we scored it as: 0 (absent); 1 (< 15%); 2
(15-50%); 3 (>50% of the areas examined). Cellularity
density was assessed as follows: 1 (<25%), 2 (25-50%) and
3 (>50%). Pleomorphism scores were 0 (absent), 1
(<25%), 2 (25-50%) and 3 (>50%). The tumours were
graded on a 3-point scale using the guidelines of Enzinger
and Weiss (1988).
Treatment
Surgery After reference to operation notes and pathology
reports surgery was coded as biopsy only, incomplete
(macroscopically or microscopically) excision, complete excis-
ion, wide excision (or amputation). Only one patient had an
amputation and was therefore included in the group having
wide excision for the purposes of analysis. All except one of
the patients had had their surgery before referral to Clinical
Oncology.
Radiotherapy This was defined as radical, palliative or none
to the primary site. Dose and fractionation schedules for
radical treatment varied according to the site of the primary
tumour, whether or not it had been excised and whether
adjuvant chemotherapy was being given. CRE values for
radical treatment ranged from 1,351 to 1,857.
Chemotherapy Chemotherapy was used either as an adju-
vant to radical radiotherapy for irresectable tumours or as
palliation. Either single agent or a combination of two or
Correspondence: J.N. El-Jabbour, Department of Histopathology,
Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK.
Received 20 November 1989; and in revised form 7 June 1990.
'PI Macmillan Press Ltd., 1990 Br. J. Cancer (1990), 62, 857-861858 J.N. EL-JABBOUR et al.
three agent therapy was used. Eleven of the 16 patients were
treated with Adriamycin containing regimes, most commonly
combined with DTIC.
Statistical methods
The following possible prognostic variables were considered:
age, sex, pain as a presenting symptom, a detectable mass at
presentation, primary site, the presence or absence of meta-
stases at presentation, extent of surgery, radiotherapy as a
primary treatment, pathological size (referred to hereafter as
size), histological type, mitotic activity, extent of necrosis,
cellularity, pleomorphism, stage and grade.
All variables were displayed in contingency tables and the
appropriate statistical tests were performed to identify statis-
tically significant associations between pairs of variables.
Univariate survival analysis was performed as an exploratory
tool to identify potential prognostic variables.
All the variables were tested for proportionality with site
coded as superficial limbs/superficial (trunk or head and
neck)/deep; radiotherapy coded as radical or palliative/none
in order to produce reasonable proportionality. The hazards
for histological type were not proportional and this variable
was therefore included in the analysis as a stratification
variable. This meant that the 13 patients with tumours of less
common histological types could not be included as they did
not form a uniform group.
Analysis was performed using the proportional hazards
regression model (Cox, 1972) to evaluate the effects of these
variables when studied simultaneously and identify indepen-
dent prognostic factors. Only 38 of the 87 patients had
tumour size recorded and therefore the analysis was per-
formed both including and excluding size as a possible prog-
nostic variable. Separate analyses were performed for
superficial and deep tumours, for irresectable tumours and
those which were resected.
Multivariate analysis was also performed including only
age, sex, site, grade, histological type, size, mitotic activity,
necrosis, pleomorphism and cellularity, the data available to
the pathologist.
Results
The clinicopathological features, including the presenting
characteristics, for the 100 STS are shown in Table I. There
were 53 males and 47 females. The majority were aged 50
years or over with the mean age being 58 years (s.d. 17.0
years). The most common symptom at presentation was a
painless mass and the duration of symptoms varied from <1
week to 10 years (median 9 months). The most common sites
were lower limb, trunk and retroperitoneum. Leiomyosar-
coma and MFH were the largest histological groups. The
mean tumour size was 9.2 cm.
Treatment
Treatment modalities are shown in Table II. Surgery was the
only treatment in 13 patients but combined with radical or
palliative XRT in another 42 and three patients respectively.
Eighteen patients were treated with radical XRT alone and
seven with palliative XRT. In 17 patients neither XRT nor
surgery was used.
Local control
Of the 10 patients treated by wide excision, six had radical
radiotherapy postoperatively and remained locally well con-
trolled while one of the four patients having no radiotherapy
recurred locally.
Of the 16 patients who had a complete excision there were
three local recurrences among the 11 who had radical radio-
therapy and two among the four who had none.
Radical radiotherapy was given postoperatively to 25 of
the 32 patients who had an incomplete excision. A complete
Table I Patient characteristics
Sex Male
Female
Age (years) 16-29
30-39
40-49
50-59
60-69
70-79
80-
Symptoms Painless mass
Painful mass
Pain
Others
Duration 0 14
Metastases at presentation
Site
UICC Stage
Pathological size
(cm)
Histological type
Grade
Mitotic activity
(in 10 hpf)
Necrosis
Pleomorphism
Cellularity
53
47
7
12
7
Mean 58.0
20
25
22
7
45
22
19
25
0 years, median 9 months
18
Lower limb
Upper limb
Trunk
Head and Neck
Retroperitoneum
Thorax
IV
III III
0-5
6-10
11-15
,16
Not known
Leiomyosarcoma
MFH
Synovial sarcoma
Liposarcoma
Neurogenic sarcoma
Other
GI
G2
G3
0-4
5-9
10- 14
15-19
20-24
25
0 (absent)
1 (<15%)
2 (15-50%)
3 (>50%)
0 (absent)
1 (<25%)
2 (25-50%)
3 (>50%)
1 (<25%)
2 (25-50%)
3 (>50%)
40
6
20
3
25
6
22
34
26
18
11
20
8
5
56
32
27
11
8
6
16
26
41
33
20
28
8
10
13
21
45
36
13
6
13
41
27
19
15
41
44
Mean 9.2
Table II Treatment modalities and local control
Radical XRT Palliative XRT No XRT to
to primary to primary primary
(60) (10) (30)
Wide excision (10) 6 4
CR 6 4
Recurrence 0 1
Complete excision (16) 11 1 4
CR 11 1 4
Recurrence 3 2
Incomplete excision (32) 25 2 5
CR 23 0 0
Recurrence 5
No surgery (42) 18 7 17
CR 5 0 0
Recurrence 2
XRT, radiotherapy; CR, complete response (clinical).STS, PROGNOSTIC FACTORS FOR SURVIVAL 859
response was achieved in 23 of these patients but five recur-
red later.
Of the 18 patients with irresectable tumours treated by
radical radiotherapy, a complete response was achieved in
five but two of these had a later recurrence.
Metastatic disease
Eighteen patients had metastatic disease at presentation. The
most common sites were liver (6), lung (5) and lymph nodes
(4). Another 35 patients developed metastases later in their
clinical course; lung (20) and liver (5) were the most common
sites.
Cause ofdeath
Only eight patients in this series were disease-free at death,
whilst a further 28 remain alive, one with local disease pre-
sent. Of the patients who died 57% had clinical evidence of
metastatic disease and 58% had local disease present.
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Figure 1 Survival by site.
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Significant associations between pairs ofvariables
From the 120 significance tests performed 31 statistically
significant associations were found compared with six which
would be expected by chance. The strongest associations
(P<0.0001) were between the following pairs of variables:
mass and site (a symptom mainly for superficial tumours);
mass and surgery (75% of patients with a mass had surgery);
site and surgery (superficial tumours were treated by more
aggressive surgery): grade and mitotic activity (the higher the
grade the higher was the mitotic count); pleomorphism and
histological type (most of the pleomorphic STS were MFH
and leiomyosarcoma); pleomorphism and grade (most of the
pleomorphic STS were grade III): cellularity and histological
type (the majority of the highly cellular STS were MFH and
leiomyosarcoma); metastases at presentation and XRT (only
two patients with metastases had radical XRT).
Survival analysis
The 2-year survival was 50.0%. The actuarial (one patient
lost to follow-up) 5 year survival rate for the 100 patients
was 21.5% and the 10 year rate 19.0%. Median survival was
23 months.
Univariate analysis
Those variables which were shown to have a significant effect
on survival were surgery (P<0.0001), radiotherapy (P<
0.0001), metastases at presentation (P<0.0001), mass as a
presenting symptom (P = 0.004), site (P = 0.002) (Figure 1),
stage (P<0.0001) (Figure 2), histological type (P=0.019)
and grade (P = 0.007). Mitotic activity was also a significant
factor whether grouped 0-4, 5-9 and >9/10 hpf (P =
0.009) or 0-9, 10-19 and > 19/10 hpf (P = 0.020) with
those.containing fewer mitoses faring better. Older patients
fared worse (P = 0.066) as did males (P = 0.0862) and
patients presenting with pain (P = 0.123). No trends were
noticed with tumour necrosis or size on univariate analysis.
Multivariate analysis
When size was excluded from the model 87 patients were
available for analysis. The following independent prognostic
factors were identified: radiotherapy (P<0.0001), surgery
(P= 0.0002), necrosis (P= 0.0080), sex (P= 0.0138) and
mitoses (P=0.0468). The favourable factors were radical
radiotherapy, more extensive surgery, little or no necrosis,
female gender and few mitoses.
When stage was included as a possible prognostic variable,
in place of grade and metastases at presentation, it was not
shown to be of any independent prognostic importance.
When size was included as a possible prognostic variable
only 38 patients were available for analysis. Size was not
p < 0.0001
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brought into the model, demonstrating that it was of no
independent prognostic value in the overall group ofpatients.
There were 42 patients with irresectable tumours. Six of
these were of the less common histological type leaving 36
for analysis. Whether or not these patients were treated by
radical radiotherapy was the only independent prognostic
factor (P = 0.0071).
Fifty-eight patients had their tumours excised. Of these,
seven had less common histological types leaving 51 patients
for analysis. For these patients only having radical radio-
therapy (P = 0.0079) and the degree of necrosis (P= 0.0193)
were of independent prognostic value.
When only the variables known to the pathologist were
included as possible prognostic factors, i.e. age, sex and the
pathological variables, (excluding size) then sex (P= 0.0223)
and mitoses (P= 0.0354) came out as significant with site
(P = 0.0510) just failing to reach the conventional level of
statistical significance. When size was included only 38 cases
were available for analysis and size was not shown to be
significant.
Superficial tumours
When size was excluded as a possible prognostic variable, 59
patients were available for analysis (10 with a less common
histological type were excluded). Histological type was
included as a stratification variable. The following indepen-860 J.N. EL-JABBOUR et al.
dent prognostic factors were identified: radical radiotherapy
(P = 0.0008), extent of surgery (P = 0.0097) and necrosis
(P = 0.0450), with radical radiotherapy, more extensive
surgery and less necrosis being favourable.
When size was included as a possible prognostic variable
only 33 patients were available for analysis. However, in this
subgroup it was the most important independent prognostic
factor (P = 0.0011), patients with smaller tumours having a
better prognosis. Also included in the model were necrosis
(P = 0.0026) and cellularity (P = 0.0203), with less necrosis
and more cellularity being favourable.
Deep tumours
There were 31 patients with tumours arising in the retro-
peritoneum or the thorax. For the analysis histological type
was recorded as leiomyosarcoma, liposarcoma or other. The
independent prognostic factors identified were histological type
(P<0.0001), sex (P = 0.0003), extent of surgery (P = 0.0168)
and radiotherapy (P = 0.0237) with cellularity (P = 0.0530)
and age (P = 0.0687) just failing to reach the conventional
level of statistical significance. Liposarcoma emerged as the
most favourable histological type for deep tumours, followed
by leiomyosarcoma and then the rest. Females had a better
prognosis than males and patients having more extensive
surgery and/or radical radiotherapy did better.
Discussion
This study was undertaken to review our experience of the
treatment of patients with STS, to analyse the prognostic
significance of histological and clinical factors and to com-
pare these with other published results. As the Oncology
Department is a specialised cancer treatment unit there may
be a bias of referral. Thus patients with larger lesions, pos-
sibly difficult to resect, and those with recurrent or metastatic
disease may make up a considerable proportion of the popu-
lation referred. The results demonstrate that several histo-
logical and clinical parameters affect prognosis.
Reappraisal of pre-review histological diagnoses is essential
since sarcomata are rare and constitute a recognised area of
diagnostic difficulty for the general histopathologist. The fact
that 17 tumours were recategorised as benign soft tissue
lesions (9) and non-sarcomatous malignancies (8) justifies our
histological review. Inclusion of these cases would have
biased the survival analysis.
The significance of grade has been demonstrated more
often than have other histological parameters but in this
series is not an independent prognostic factor. However, the
independent significance of two of the STS grading criteria,
necrosis and mitotic activity, indirectly emphasise the impor-
tance of histological grade and suggest that necrosis and
mitotic activity may be the most important factors in assess-
ing grade. These two factors seem to be related to the
tumour proliferative activity which can be assessed by stain-
ing frozen sections of tumours with the monoclonal antibody
Ki-67. Initial investigations by Ueda et al. (1989) indicate a
significant correlation between survival and tumour reactivity
for Ki-67 which might be used as one of the histological
factors for grading STS.
Costa et al. (1984) demonstrated the effect of extent of
necrosis on survival and used it in their grading system. Since
then other authors (Mandard et al., 1989; Rooser et al.,
1988; Trojani et al., 1984) have, like us, shown it to be an
independent prognostic factor. Assessment of the extent of
necrosis is the most subjective and difficult of the criteria
used in grading (Costa et al., 1984; Trojani et al., 1984). A
systematic approach to STS, including assessment of necrosis
should be developed by all pathologists.
There have been conflicting reports regarding the prognos-
tic significance of size and site. Since there is always a degree
of tissue reaction around the tumour the clinical size is not
an accurate reflection of tumour volume. Pathological size is
probably best used in analysis. The prognostic significance of
overall size (Mandard et al., 1989; Ueda et al., 1988) and site
(Collin et al., 1987; Markhede et al., 1982) is well docu-
mented in the literature. In this study, size was an indepen-
dent prognostic factor in the superficial STS but not in either
the overall group or the deep STS. As expected, due to the
surgical problems and, probably, the nature of such tumours,
survival was poor for patients with retroperitoneal disease
(Bramwell et al., 1985; Collin et al., 1987; Markhede et al.,
1982; Tsujimoto et al., 1988). Since retroperitoneal STS tend
to be larger at presentation it is difficult to separate size from
site as an independent prognostic factor. In this study, few
deep STS were completely resected which meant that their
pathological size was unknown and could not be included in
the proportional hazards model.
In this review the UICC staging, a modified version of the
AJC staging, was used. It proved to be of prognostic value
only on univariate analysis.
The prognostic significance of symptoms has been reported
by Collin et al. (1987) and Ueda et al. (1988). Heise et al.
(1986) found a higher recurrence-free survival in patients
presenting with mass as compared with other symptoms. The
wide range of duration of symptoms has been shown by
others (Bramwell et al., 1985; Ueda et al., 1988) and prob-
ably relates to the fact that many patients ignore any swelling
not accompanied by pain. In our series there was an associa-
tion of symptoms with site and they did not prove to be of
prognostic significance.
The prognostic significance of sex, age and local recurrence
has also been reported by one or more investigators (Bram-
well et al., 1985; Collin et al., 1987; Markhede et al., 1982;
Pinedo et al., 1984; Tsujimoto et al., 1988). Only sex was of
prognostic importance in our series.
The mode of treatment affects survival (Dewar & Duncan,
1985). In our series radical surgical treatment and radio-
therapy were associated with better survival. There have been
many reports on the role of surgical excision alone or fol-
lowed by adjuvant radiotherapy (Abbas et al., 1981; Coe et
al., 1981; Dewar & Duncan, 1985; Markhede et al., 1982;
Ueda et al., 1988). A poor survival in patients with unresect-
able tumours, irrespective of further treatment has been
shown by Suit et al. (1985) and Gerner et al. (1975). Various
methods of surgical treatment seem to relate to different rates
of local recurrence (Markhede et al., 1982; Shieber et al.,
1961; Shiu et al., 1975); this may be simply a reflection of the
inadequacy of surgical excision (Abbas et al., 1981; Bell et
al., 1989; Collin et al., 1987; Mandard et al., 1989). Radical
local excision as described by Simon and Enneking (1976)
resulted in a local control rate of 98% in their series of 46
patients. Such extensive surgical approaches frequently
involve considerable mutilation and in many cases may be
technically impossible. Although initially suggested by Cade
(1951) the role of radiotherapy has only relatively recently
been established for local control of STS. By treating 64
patients with local (radical) radiotherapy following simple
excision of the tumour Suit et al. (1975) reported a local
control rate of 90.6%. Subsequently Rosenberg et al. (1982)
stressed the effectiveness of local radiotherapy for local con-
trol, avoiding mutilating surgery. In a recent report (Suit et
al., 1985) comparing the pooled data of various institutions,
the local failure rate was 18.1% for the patients treated by
radical surgery or amputation and 18.3% for the patients
treated by conservative surgery and postoperative radiation.
In our series these figures are 10% and 22.2% respectively.
The following variables have been reported by one or more
authors as being independent prognostic factors: age, sex,
symptoms, site, depth, size, tumour borders, differentiation,
mitotic activity, tumour necrosis, grade, surgical treatment,
adequacy of surgical excision, adjuvant chemotherapy, local
recurrence and nodal metastases (Collin et al., 1987; Heis et
al., 1986; Mandard et al., 1989; Markhede et al., 1982;
Trojani et al., 1984; Tsujimoto et al., 1988; Ueda et al.,
1988). Our results are within this wide range of findings.
They also show the independent significance of radical radio-
therapy as a primary or adjuvant treatment.
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depending on their relation to the deep fascia. While these
definitions are acceptable for STS ofthe extremity and trunk,
they do not apply to the retroperitoneal and thoracic STS.
The results of the multivariate analyses done on the super-
ficial STS are as expected. Smaller tumours are more
amenable to adequate surgical treatment and radiotherapy.
Extent of necrosis tends to reflect the rate of proliferative
growth which is in turn related to survival (Ueda et al.,
1989).
In summary our clinical findings are in broad agreement
with the literature. Our survival analyses reaffirm the impor-
tance of radical treatment. They also demonstrate that cer-
tain histological features, i.e. necrosis and mitotic activity,
are of special significance and they probably relate to assess-
ment ofgrade more than any ofthe other factors currently in
use. Future studies to determine prognostic factors should
include cell kinetics to assess their contribution in predicting
biological behaviour and survival. Although the number of
cases in this study is not small the subgroups are and we
believe that there is a need for further larger co-operative,
studies to standardise assessment of grade and to identify
prognostic factors. Only by such collaboration can we
develop a better clinicopathological understanding of soft
tissue sarcomata.
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